Company: PCAP
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001213900-25-042690
Chunk: 213

Company: ProCap Acquisition Corp
Filing Date: 2025-05-13
Form: S-1/A
Chunk 213
---
, from July 2018 to August 2019. Additionally, Mr.Buchanan has served on the board of directors of Argus Monitoring Solutions since February 2022. Mr.Buchanan earned a degree in Economics from Samford University and an MBA from the University of Kentucky. We believe Mr.Buchanan is well qualified to serve as a member of our board of directors due to his extensive strategic, operational and broad business experience. Past performance of our management team or our advisor or their respective affiliates is not a guarantee either (i) of success with respect to any business combination we may consummate or (ii) that we will be able to identify a suitable candidate for our initial business combination. You should not rely on the historical performance record of our management team or their affiliates as indicative of our future performance. Our officers and directors may have conflicts of interest with other entities to which they owe fiduciary or contractual obligations with respect to initial business combination opportunities. For a list of our officers and directors and entities for which a conflict of interest may or does exist between such persons and us, as well as the priority and preference that such entity has with respect to performance of obligations and presentation of business opportunities to us, please refer to the table and subsequent explanatory paragraph under “Management — Conflicts of Interest.” Our Advisor Brenton L. Saundersis serving as a Special Advisor to the Company. Mr. Saunders has served on the board of directors of TBHC since May 4, 2021 and currently serves as its chairman of the board. Mr. Saunders briefly served as Interim Chief Executive Officer of TBHC in January and February 2022, and as TBHC’s executive chairman of the board of directors for the fiscal year of 2022 until March 2023. Mr. Saunders has over 25 years of experience in various aspects of healthcare and has been in leadership roles at several prominent global pharmaceutical and healthcare companies. Until May 2020, when it was acquired by AbbVie Inc. in a transaction valued at approximately $63 billion, Mr. Saunders served as Chairman, President and Chief Executive Officer of Allergan plc (“Allergan”), an American, Irish -domiciledpharmaceutical company. His role as president and chief executive officer of Allergan began in July 2014 and his added role of chairman began in October 2016. Mr. Saunders’ first role as an executive officer in the pharmaceuticals and healthcare sectors began in 2003, as a member of the executive management